Method of increasing coronary pO{HD 2 {B in mammals

ABSTRACT

Adenosine-5&#39;&#39;-carboxylic acid amides represented by the formula   wherein R1 and R2 are each selected from the group consisting of hydrogen, loweralkyl, lowerhaloalkyl, lowerhydroxyalkyl, lowercycloalkyl, loweralkylcycloalkyl, loweralkenyl, lowerhaloalkenyl, lowerhydroxyalkenyl, loweralkynyl, lowerhaloalkynyl, benzylamino, phenyl, loweralkylphenyl, loweralkoxyloweralkyl, substituted phenyl, 2-methylfuran or di(C1-C4)alkylamino(C1-C4)alkyl, adamantyl or R1 and R2 taken together form a five or six membered heterocyclic moiety; R3 and R4 are hydrogen or acyl, or taken together form an isopropylidene or a benzylidene group; or a pharmaceutically acceptable acid addition salt thereof.

United States Patent [191 Stein et al.

[451 Oct. 21, 1975 METHOD OF INCREASING CORONARY PO IN MAMMALS [75] Inventors: Herman Hal Stein, Skokie, l1l.; Raj

Nandan Prasad, Pierrefonds,

Canada [73] Assignee: Abbott Laboratories, North Chicago, 111. i

[22] Filed: July 30, 1974 211 App]. No.: 492,949

Related US. Application Data [60] Division of Ser. No. 370,084, June 14, 1973, Pat. No. 3,864,483, which is a division of Ser. No. 236,980, March 22, 1972, which is a continuation-in-part of Ser. No. 125,893, March 18, 1971, abandoned.

[52] US. Cl 424/180; 260/211.5 R [51] Int. Cl. A61K 27/12 [58] Field of Search 424/180; 260/21 1.5 R

[56] References Cited UNITED STATES PATENTS 3,697,504 10/1972 Schmidt 260/211.5 R 3,864,483 2/1975 Stein et al 424/180 FOREIGN PATENTS OR APPLICATIONS 2,034,785 1/1972 Germany Primary ExaminerShep K. Rose Attorney, Agent, or Firm-Robert L. Niblack; Vincent A. Mallare [57] ABSTRACT Adenosine-5-carboxylic acid amides represented by the formula 1 Claim, No Drawings METHOD OF INCREASING CORONARY Po IN MAMMALS CROSS-REFERENCE TO RELATED APPLICATION This is a division of application Serf No. 370.084 filed June 14, 1973, now U.S. Pat. No. 3,864,483 issued Feb. 4, 1975, which is a divisional of application Ser. No. 236,980 filed Mar. 22, 1972. which is a continuation-in-part of application Ser. No. 125,893 filed Mar. 18, 1971, now abandoned.

DETAILED DESCRIPTION OF THE INVENTION This invention relates to adenosine derivatives and more particularly relates to adenosine--carboxylic acid amides, to intermediates useful in their preparation and to methods of using the compounds.

The compounds of this invention are represented by the formula wherein R, and R are each selected from the group consisting of hydrogen, loweralkyl, lowerhaloalkyl, lowerhydroxyalkyl, lowercycloalkyl. loweralkylcycloalkyl, loweralkenyl, lowerhaloalkenyl, lowerhydroxyalkenyl, loweralkynyl, lowerhaloalkynyl. benzylamino, phenyl, loweralkylphenyl, loweralkoxyloweralkyl, substituted phenyl. 2-methylfuran or di(C,-C )alkylamino (C -C )alkyl, adamantyl or R and R taken together form a five or six membered heterocyclic moiety; R and R are hydrogen or acyl, or taken together form an isopropylidene or a benzylidene group; or a pharmaceutically acceptable acid addition salt thereof. Compounds wherein R and R are hydrogen are useful in treating cardiovascular disorders and are particularly useful as anti-hypertensive and antianginal agents. A number of amides also exhibit antiinflammatory activity.

The term loweralkyl as used herein refers to C C straight and branched chain alkyl groups including methyl, ethyl, n-propyl, iso-propyl, n-butyl. sec-butyl, tert-butyl. iso-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, iso-hexyl and the like.

The term loweralkenyl refers to alkenyl groups having from 2-6 carbon atoms such as vinyl, allyl, methallyl, l-pentenyl and the like.

The term loweralkynyl refers to C C. alkynyl groups including ethynyl, propargyl, Z-butynyl, lpentynyl and 2-hexynyl.

The term halo" includes chloro, fluoro, bromo and iodo.

The term lowercycloalkyl refers to C -,C cycloalkyl groups and includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

The term "loweralkylcycloalkyl" refers to C -C cycloalkylloweralkyl groups such as cyclopropylmethyl and the like.

The term alkoxyloweralkyl" refers to alkoxyalkyl groups having a total of no more than six carbon atoms such as methoxymeth'yl. methoxyethyl. ethoxyethyl. propoxypropyl. propoxyethyl and the like.

, The term substituted phenyl" refers to a phenyl group substituted in the ortho. meta or para position by a loweralkyl, loweralkoxy or halo atom or a disubstituted phenyl group containing two of the above mentioned radicals such as 3.4-dimethoxyphenyl. 3.5- dimethylphenyl, 3-chloro-4-methylphenyl and the like.

The term five or six membered heterocyclic moiety" includes morpholino. thiomorpholino. piperidino. homopiperidino. piperazino. pyrrolidino and the like.

The term pharmaceutically acceptable acid addition salts" refers to salts prepared by reacting the amide with an organic or inorganic acid. Representa tive salts include hydrochloride. hydrobromide. sulfate. bisulfate. acetate. valerate. oleate. laurate. borate. benzoate, lactate, phosphate. tosylate. citrate. maleate. succinate. tartrate. napsylate and the like.

Representative compounds of this invention include: adenosine-5-carboxamide: adenosine-5'-(N-methyl)- carboxamide: adenosine-5'-(N-iso-propyl)carboxamide; adenosine-5 Nethyl )-carboxamide; adenosine- 5-(N-n-propyl)carboxamide; adenosine-5'-(N-isobutyl)carboxamide; adenosine-5-(N-n-butyl)carboxamide; adenosine-5-(N-n-pentyl)carboxamide; adenosine-5'-(N-iso-pentyl)carboxamide; adenosine-5'-(N.N- dimethyl)carboxamide; adenosine-5-(N.N-diethyl)- carboxamide; adenosine-5'-(N.N-diisopropyl)carboxamide; adenosine-5-(N-methyl-N-ethyl)carboxamide; adenosine-5-(-N-cyclobutyl)carboxamide; adenosine- 5-(N-cyclopropylmethyl)carboxamide; adenosine-5- (N-propargyl)-carboxamide: adenosine-5-(N-allyl)- carboxamide; adenosine-5'-(N-ethoxyethyUcarboxamide; adenosine-5 N,N-dicyclopropylmethyl )carboxamide; adenosine-5'-(N,N-dichloroethyl)carboxamide.

The compounds of this invention are useful as blood pressure lowering agents when administered to hypertensive patients in dosages of from 0.001-25 mg./kg. of body weight daily. The compounds are also useful in the management and treatment of angina pectoris when administered to patients suffering from or prone to such attacks in dosages of from 0.001-25 mg./kg. of body weight daily. In both instances, it is preferred to administer the compounds orally, however. the compounds may also be administered via intravenous administration. The compounds can be administered in single doses, however, it .is preferred that they can be administered in divided doses, i.e.. 3-4 times daily.

In addition to their cardiovascular activity, a number of amides exhibit anti-inflammatory activity at dosages of 0.04 to mg./kg. of body weight, with a number of the compounds having an ED in the rat paw edema test of under 1 mg./kg.

The compounds of this invention can be prepared by converting adenosine-5-carboxylic acid (prepared from 2',3-isopropylidene adenosine according to the method described by Harmon et al, Chem. Ind. 1969, 1141 to the corresponding acid chloride by reacting it with thionyl chloride and then reacting the acid chloride with ammonia or an appropriately substituted alkyl amine such as methylamine, dimethylamine and the like. It will be obvious to those skilled in the art that other well-known procedures can also be employed to prepare the compounds of this invention.

The 2.3'-hydroxyl groups of the starting acid can be temporarily blocked by using the protective groups which are conventional in sugar chemistry. The protecting groups can be acyl groups, preferably acetyl or benzoyl groups, or ketals, such as the 2',3- isopropylidene or benzylidene, which can be converted back to the 2,3'-dihydroxy compounds by methods well-known in the art. preferably after the conversion of the acid chloride to the amide. The 2',3- isopropylidene adenosine starting material is commercially avialable from Pfanstiehl Corporation, North Chicago, Illinois and the preparation thereof is well known. A number of the intermediates also exhibit cardiovascular activity.

The preferred synthetic route is represented by the following reaction scheme:

N l- N t s N N i ii HOC soci ClC o o P zi \CH; CH CH3 l NH- NH. HN

z I 1 \R2 N/ N N -N k k N -N i i R.

\N( H Nc R2/ 2/ o 0 OHOH C CH,/ \CH,

The following examples further illustrate the present invention:

EXAMPLE 1 2',3'-lsopropylidene Adenosine-5-Carboxylic Acid Chloride 2',3-lsopropylidene adenosine-5'-carboxylic acid (12.8 g.) [prepared according to the method of R. E. Harmon. et al, Chem. Ind. London, N0. 33, 1141 (1969)] was added to an excess of thionyl chloride (70 ml.) at 0C. The mixture was stirred for 1 hour at 0C.

and then the temperature was allowed to go up to room temperature for another hour. The clear solution was poured, in a thin stream, onto a large volume of well stirred dry ether. The yellow precipitate of 2',3- isopropylidene adenosine-5'-carboxylic acid chloride, m.p. l90195 dec. was filtered and washed with an excess of dry ether. This material was used directly for the preparation of the amides without any further purification.

EXAMPLE 2 Adenosine-5-Carboxamide A mixture of 6.8 g. of 2',3-isopropylidene adenosine-S '-carboxylic acid chloride and ml. of liquid anhydrous ammonia was stirred for 2 hours at 60 to 50C. At the end of this time the ammonia was allowed to evaporate off at room temperature. The residue was triturated with cold aqueous sodium bicarbonate solution (IN). The resulting insoluble solid was filtered, washed with cold water and recrystallized from ethanol to yield 3.5 g. of crude 2',3- isopropylidene adenosine-S-carboxamide, m.p. 220222. The amide was then mixed with 100 ml. of 1 N hydrochloric acid and maintained at a temperature of between 70 for 45 minutes. The acidic solution was then cooled, neutralized with sodium bicarbonate and the mixture evaporated to dryness under reduced pressure. The residue was recrystallized three times from absolute ethanol to yield 1 gram of pure adenosine-S'-carboxamide, m.p. 245-247; [a],, 29 0.9 (c, 1.08 in IN HCl). Elemental analysis and nuclear magnetic resonance data confirmed the identity of the compound.

EXAMPLE 3 Adenosine-5 N-methyl )Carboxamide 2, 3-lsopropylidene adenosine-S'-[N-methylcarboxamide] (m.p. 264-265) was prepared according to the method of Example 2 from 2, 3-isopropylidene adenosine-5-carboxylic acid chloride and an excess of dry liquid methylamine at 20 to 10C. The 2', 3'- isopropylidene group was cleaved by the use of 1N HCl at 60 for 45 minutes to give adenosine-5'-(N-methyl)- carboxamide in 44% yield; m.p. 240-241; [a],, 23 i 0.6" (c, 3.2 in IN HCl). Elemental analysis and nuclear magnetic resonance data confirmed the identity of the compound.

EXAMPLE 4 Adenosine-5 -(N,N-dimethyDCarboxamide 13.5 g. of 2,3-isopropylidene adenosine-5- carboxylic acid chloride was stirred with excess dry dimethylamine at 10 to 0C. The clear solution was allowed to Warm to room temperature. In about 3 hours the unreacted dimethylamine had evaporated off. The residue was washed with ether and dissolved in the minimum amount of cold aqueous NaHCO solution (IN). The basic aqueous solution so obtained was extracted five times with 50 ml. of chloroform. The chloroform extract was dried and evaporated under reduced pressure to give an amorphous solid. This solid was dissolved in dilute acetic acid, filtered (to remove a small amount of insoluble material) and the filtrate was extracted four times with 50 m1. of chloroform. The chloroform extract was dried and evaporated to dryness under reduced pressure to yield 6.0 g. (43%) of 2,3isopropylidene adenosine- 5 -(N,N-dimethyl)carboxamide. The crude amide (m.p. 106l10) was dissolved in ml. of 1N HCl and kept at 6070 for 45 minutes. The solution was then cooled, basified with NaHCO and evaporated to dryness under reduced pressure.

The residue, upon recrystallization three times from absolute cthunolfgave 3.0 g. (23%) of adenosinc-5'- (N.N-dimethyl)carhoxamidc as a monohydratc; m.p. 190-19l; [82],, 17i-0.3 (c, 3 in IN HCl). Elemental analysis and nuclear magnetic resonance data confirmed the identity of the compound.

EXAMPLE 5 Adenosine-S N-ethyl )-Carboxamidel Freshly prepared 2, 3-isopropylidene aden0sine-5- carboxylic acid chloride (prepared from 6.4 g. of 2, 3-isopropylidene-5-carboxylic acid) was stirred with excess of dry liquid ethyl amine at 50 to 35. The clear red-orange solution was allowed to warm up to room temperature and kept at this temperature for hours. At the end of this period the excess of ethyl amine had evaporated off. The residue was triturated with cold a qeuous NaHCO solution. The white precipitate was filtered off and washed with a small amount of cold water to yield 3.1 g. (44.5%) of crude 2, 3'-

6 isopropylidene-S-[(N-ethyl)-carboxamide] m.p. 225-227. R 0.72 (silica gel) system: n.BuOH:- H OzNH OH (86:14:5). The above amide was mixed with 80 ml. of 1 N HCl and kept at for 45 minutes. The acidic solution was then cooled and basified with NaHCO The mixture was then evaporated to dryness under reduced pressure, and the residue recrystallized twice from absolute ethanol and finally from water. The white crystalline product was dried in vacuo for 2 days over P 0 at -78 to give 0.9 g. (32%) of adenosine-S-[(N-ethyl)carboxamide]which melted slowly at l36-172 and solidified again at l48l50 and finally melted at 246-247 (sharp). [01], (c, 0.92 in 1 N HCl); R 0.51 (silica gel). System: n.BuOH:H O:NH OH (86:14:05); NMR (deuterated DMSO) peaks (in ppm) at 5.6 (2-OH. 3-OH). 7.4 (6C-NH 8.8 (CONH); 3.2 (CH CH Elemental analysis and NMR data confirmed the identity of the compound.

Recrystn. [a],, D Example R, R MpC. Solvent Rotation C/lNHCl 6 -C H, H 246-247 H 0 16.3:0.54 0.92 0.51 7 C H OC H H 107-110 EtOH 5 7.4i0.9 0.54 0.44 4 CH 8 CH H 137-141 EtOH 9:2.2 0.223 0.53

CH, 9 (CH CH H 104-106 DMF 8.9- -1.5 0.334 0.56 10 CH -CH=CH H 223-224 EtOH 13.5i1.4 0.369 0.50 11 CH C' CH H -137 EtOH 27.5:0.5 0.44 0.44 12 4 H 249-250 EtOH -6.8i0.8 0.584 0.47 13 CH H 130-133 H O 6.31-1.5 0.315 0.55

14 (CH );,CH;, H 125 Me0H-Acetone 15 (CH CH H 220-222 MeOH-Acetone- Ether CH CH 16' cn H a MeOH-EtOEt 1.610.8 0.63

CH CH 17 CH COOC H H -170 Acetone- 3.710.23 2.16

Ether a-no sharp melting point "-TLC was done on Eastman 6060 Silica Gel Chromagram Sheet with Fluorescent indicator. Solvent System used was: nBuOH:NH OH:H,O=86:5:14

ANALYSES Calculated Found Example Contd. Empirical Formula C H N O C H N O 6 C, H N O .%H,O 45.42 5.40 26.48 22.68 45.76 5.87 25.51 22.48 7 C H N QV, 47.73 5.72 23.85 22.70 47.49 5.85 24.05 23.01 8 C H N O 48.49 5.62 26.05 19.83 48.28 5.78 26.25 20.21 9 C H N ofl/H O 51.47 6.75 22.51 19.28 51.52 6.69 22.41 19.13 10 C H N O H O 46.20 5.36 24.82 23.62 46.28 5.58 24.90 24.00 11 C -,H N O 49.10 4.43 26.38 20.09 49.15 4.60 26.59 20.48 12 C H N O. 48.79 5.83 26.22 19.96 48.98 5.52 25.81 19.41 13 H N 0 55.13 4.90 22.69 17.28 54.83 5.00 22.91 17.71 14 C H N O, 49.98 5.99 24.98 19.02 50.12 6.06 25.14 19.35 15 C H N O .CH OH 47.44 6.25 23.71 22.57 47.00 5.80 24.86 22.69 16 C H N O 51.41 6.33 23.98 18.26 50.39 6.36 23.55 17.36 17 c H N O 51.71 5.78 24.12 18.37 51.51 6.06 24.17 18.75

Examples Contd. R,(1) Empirical Formulae and Microanalysis 26 0.59 C H N O N, 24.97; 0, 19.46 27 0.43 C13H gN3o5(2) 28 0.35 C H, N,O (2) 29 0.51

Calcd. C. 50.52; H. 6.36; N. 22.09; 0, 21.03 Found. C. 49.80; H, 6 CIGHZONBOG Calcd. C, 48.98; H, 5.14; N, 0, 24.47 Found. C, 47.96; H. 5.19; N, 0, 24.58

Found. C. 53. 0.66 C H N O Calcd. C, 53 Found. C, 53.

1. R values are obtained from the TLC. Unless other- Th compounds of this invention can be formulated W pe ifie Solvent system used Was! HBUOHIN- into various pharmaceutically acceptable dosage forms 30 such as tablets, capsules, pills and the like for immedi- H OH:H O: 86: in the TLC.

5:14. All compounds had a single spot ate or sustained releases by combining the active com- 2. The total of the percentage composition of all the elements (C. H,N & 0) determined by the analyst was pound with suitable pharmaceutically acceptable carri ers or diluents according to methods well-known in the y 95% or 9 The Compounds had a single P in art. Such dosage forms may automatically include exthe TLC. Their structures were followed by the mfra- 35 cipiemsy binders. fillers flavoring and sweetening red spectra and confirmed by the nmr.

agents and other therapeutically inert ingredients necessary in the formation of the desired preparation.

3. Solvent system: n-Butanol saturated with water.

While all of the compounds of this invention exhibit cardiovascular activity, only certain of the compounds exhibit anti-inflammatory activity. summarizes the anti-inflammatory paw edema assay:

Preparations for parenteral administration include sterile, aqueous or non-aqueous solutions, suspensions or emulsions which are well-known in the art.

The following table activity in the rat w l im;

1. A method of increasing coronary p0 in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of the formula R: is H in each of the above compounds amine for diethylamine. 

1. A METHOD OF INCREASING CORONARY PO2 IN A MAMMAL IN NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO SAID MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF THE FORMULA 